Press Releases

Date Title
11/5/20 Sarepta Therapeutics Announces Third Quarter 2020 Financial Results and Recent Corporate Developments
11/5/20 Sarepta Therapeutics to Commence Dosing of the Next Study with Commercial Process Material for the SRP-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy
11/2/20 Sarepta Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
10/29/20 Sarepta Therapeutics to Announce Third Quarter 2020 Financial Results and Recent Corporate Developments on November 5, 2020
10/22/20 Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics
9/30/20 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/28/20 Sarepta Therapeutics Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Functional Improvements 18-months After Administration
9/28/20 Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
9/15/20 Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
9/14/20 Long-term functional data from Sarepta Therapeutics’ Most Advanced Gene Therapy Programs to be Presented at Upcoming Annual Congress of the World Muscle Society
Displaying 81 - 90 of 730